Vericel to Present at 28th Annual ROTH Conference
March 09 2016 - 7:46PM
Vericel Corporation (Nasdaq:VCEL), a leading developer of
patient-specific expanded cellular therapies for the treatment of
severe diseases and conditions, today announced that Nick
Colangelo, president and CEO, and Gerard Michel, chief financial
officer and vice president of corporate development, will present
at the 28th Annual ROTH Conference at The Ritz-Carlton Hotel
in Dana Point, California, on Tuesday, March 15, 2016, at 11:30am
Pacific time.
The presentation will be webcast live and may be accessed from
the events and presentations section of the Vericel
website: http://investors.vcel.com/events.cfm.
About Vericel Corporation
Vericel Corporation is a leader in developing patient-specific
expanded cellular therapies for use in the treatment of patients
with severe diseases and conditions. The company markets two
autologous cell therapy products in the United States: Carticel®
(autologous cultured chondrocytes), an autologous chondrocyte
implant for the treatment of cartilage defects in the knee, and
Epicel® (cultured epidermal autografts), a permanent skin
replacement for the treatment of patients with deep-dermal or
full-thickness burns comprising greater than or equal to 30 percent
of total body surface area. Vericel is also developing MACI™, a
third-generation autologous chondrocyte implant for the treatment
of cartilage defects in the knee, and ixmyelocel-T, a
patient-specific multicellular therapy for the treatment of
advanced heart failure due to ischemic dilated
cardiomyopathy. For more information, please visit the
company's website at www.vcel.com.
CONTACT: Chad Rubin
The Trout Group
crubin@troutgroup.com
(646) 378-2947
or
Lee Stern
The Trout Group
lstern@troutgroup.com
(646) 378-2922
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Apr 2023 to Apr 2024